STIMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Neuronetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91+0.02 (+1.33%)
Close on Oct 19, 2026
- Market cap
- $139.68M
- P/E (TTM)
- –
- Dividend yield
- –
Neuronetics, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Clinic Service | $86.98M | $4.45M | – | – | 58.3% | +1856.7% |
| Med Device | $62.18M | $70.45M | $71.35M | $65.21M | 41.7% | -11.7% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | YoY |
|---|---|---|---|---|---|
| Med Device | $3.24M | -$4.61M | -$5.13M | -$35.11M | -170.4% |
| Clinic Service | -$3.17M | $365.00K | – | – | -967.7% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Greenbrook | $86.98M | $4.45M | – | – | 58.3% | +1856.7% |
| NeuroStar | $62.18M | $70.45M | $71.35M | – | 41.7% | -11.7% |
By region
From the segment and revenue-disaggregation notes of Neuronetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.